drugset
drugset / Trial / NCT04625907

FaR-RMS: An Overarching Study for Children and Adults With Frontline and Relapsed RhabdoMyoSarcoma

NCT04625907 ↗

Phase 1/2 Recruiting 1672 enrolled University of Birmingham
RandomizedParallel-groupOpen-labelTreatment

Summary

FaR-RMS is an over-arching study for children and adults with newly diagnosed and relapsed rhabdomyosarcoma (RMS)

Timeline

Start
2020-09-17
Primary completion
2030-06
Completion
2030-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Cyclophosphamide Other / unclassified 25 mg/m2 Oral
Subject Dactinomycin Protein / enzyme biologic 1.5 mg/m2 Intravenous
Comparator Doxorubicin Other / unclassified 30 mg/m2 Intravenous
Subject Ifosfamide Small molecule 3 g Intravenous
Subject Irinotecan Small molecule 20 mg/m2 Intravenous
Subject Irinotecan Small molecule 50 mg/m2 Intravenous
Subject Regorafenib Small molecule 65 mg/m2 Oral
Subject Regorafenib Small molecule 82 mg/m2 Oral
Subject Regorafenib Small molecule 120 mg Oral
Comparator Temozolomide Small molecule 125 mg/m2 Oral
Comparator Temozolomide Small molecule 150 mg/m2 Oral
Subject Vincristine Small molecule 1.5 mg/m2 —
Subject Vinorelbine Small molecule 25 mg/m2 Intravenous
Subject Vinorelbine Small molecule 60 mg/m2 Intravenous

Indications

rhabdomyosarcoma